` CSLLY (CSL Ltd) vs S&P 500 Comparison - Alpha Spread

CSLLY
vs
S&P 500

Over the past 12 months, CSLLY has underperformed S&P 500, delivering a return of -19% compared to the S&P 500's +13% growth.

Stocks Performance
CSLLY vs S&P 500

Loading
CSLLY
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
CSLLY vs S&P 500

Loading
CSLLY
S&P 500
Difference
www.alphaspread.com

Performance By Year
CSLLY vs S&P 500

Loading
CSLLY
S&P 500
Add Stock

Competitors Performance
CSL Ltd vs Peers

S&P 500
CSLLY
ABBV
AMGN
GILD
VRTX
Add Stock

CSL Ltd
Glance View

In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.

CSLLY Intrinsic Value
82.64 USD
Overvaluation 1%
Intrinsic Value
Price
Back to Top